TY - JOUR T1 - GSK-3 inhibitors for Alzheimer's disease. AU - Avila,Jesús, AU - Hernández,Félix, PY - 2007/11/14/pubmed PY - 2008/1/3/medline PY - 2007/11/14/entrez SP - 1527 EP - 33 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 7 IS - 11 N2 - Glycogen synthase kinase (GSK)-3 has been proposed as the link between the two histopathological hallmarks of Alzheimer's disease, the extracellular senile plaques made of beta-amyloid and the intracellular neurofibrillary tangles made of hyperphosphorylated tau. Thus, GSK-3 is one of the main tau kinases and it modifies several sites of tau protein present in neurofibrillary tangles. Furthermore, GSK-3 is able to modulate the generation of beta-amyloid as well as to respond to this peptide. The use of several transgenic models overexpressing GSK-3 has been associated with neuronal death, tau hyperphosphorylation and a decline in cognitive performance. Lithium, a widely used drug for affective disorders, inhibits GSK-3 at therapeutically relevant concentrations and has been demonstrated to prevent tau phosphorylation. In this review, we summarize all these data and discuss the potential of GSK-3 inhibitors for Alzheimer's disease therapy, as well as some of their potential problems. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/17997701/GSK_3_inhibitors_for_Alzheimer's_disease_ DB - PRIME DP - Unbound Medicine ER -